AVBP NASDAQ
ArriVent BioPharma, Inc.
1W: -18.3%
1M: -47.4%
3M: -48.7%
YTD: -26.0%
1Y: -17.2%
$15.40
+0.04 (+0.26%)
Weekly Expected Move ±26.1%
$10
$16
$21
$26
$32
Credit Risk of going bust: lower than 76% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), ArriVent BioPharma, Inc. would be worth roughly what it owes.
Total debt $351K against a stock market value of $759.3M.
Distance to default 8.74 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $176K (short-term plus half of long-term), stock volatility 91.5%; Altman Z'' 13.01. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), ArriVent BioPharma, Inc. would be worth roughly what it owes.
Total debt $351K against a stock market value of $759.3M.
Distance to default 8.74 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $176K (short-term plus half of long-term), stock volatility 91.5%; Altman Z'' 13.01. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (86)
At a glance: stocks gapping up premarket
AVBP Stock Earnings Estimates Increased by HC Wainwright
ArriVent plunges as lead asset fails in late-stage cancer trial
ArriVent BioPharma (NASDAQ:AVBP) Reaches New 12-Month Low – What’s Next?
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of “Moderate Buy” from Analysts
103,931 Shares in ArriVent BioPharma, Inc. $AVBP Acquired by Bank of New York Mellon Corp
Bank of America Corp DE Grows Holdings in ArriVent BioPharma, Inc. $AVBP
Deutsche Bank AG Acquires Shares of 39,180 ArriVent BioPharma, Inc. $AVBP
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Dimensional Fund Advisors LP Has $2.92 Million Stock Holdings in ArriVent BioPharma, Inc. $AVBP
Affinity Asset Advisors LLC Purchases 25,000 Shares of ArriVent BioPharma, Inc. $AVBP
ArriVent BioPharma Q1 2026 Earnings: EPS Miss Reflects Increased R&D Spending; Shares Edge Higher - Quarterly Financial Update - dars.gov.et
(AVBP) Volatility Zones as Tactical Triggers - Stock Traders Daily
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ArriVent BioPharma (AVBP) Edges Lower Amid Consolidation Near Key Levels - Elliott Wave Entry - dars.gov.et
Citi's picks and pans for H2 '26: REITs, tech, consumer, health
ArriVent BioPharma (AVBP) Posts Modest Gain at $34.0, Hovers Near Resistance - Fundamentals - dars.gov.et
AVBP Forecast — Price Target — Prediction for 2027 - TradingView
ArriVent BioPharma (AVBP) director receives 13,562 stock options at $31.74 - Stock Titan
ArriVent BioPharma (AVBP) Stock Valuation After Growing Expectations For EGFR Firmonertinib Trials - simplywall.st
EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight
Guggenheim Remains a Buy on ArriVent BioPharma, Inc. (AVBP) - The Globe and Mail
The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight
AVBP Q1 2026 Earnings: EPS Misses Estimates as Clinical Progress Drives Stock Rally - Annual Report - dars.gov.et
Truist Financial Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $45 - Moomoo
(AVBP) Risk Channels and Responsive Allocation - Stock Traders Daily
(AVBP) Risk Channels and Responsive Allocation - Stock Traders Daily
(AVBP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case - Seeking Alpha
ArriVent BioPharma Reports First Quarter 2026 Financial Results
ArriVent BioPharma Reports First Quarter 2026 Financial Results
ArriVent BioPharma (NASDAQ: AVBP) posts Q1 2026 loss and details oncology pipeline progress - Stock Titan
A Look At ArriVent BioPharma (AVBP) Valuation After FDA IND Clearance For ARR-002 - simplywall.st
ArriVent BioPharma (NASDAQ: AVBP) adds $250M ATM stock flexibility - Stock Titan
ArriVent (Nasdaq: AVBP) Q1 2026 loss narrows while pivotal cancer trials progress - Stock Titan
ArriVent Phase 3 and Phase 1 cancer trials backed by $326M through 2027 - Stock Titan
A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate
A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate - Yahoo Finance
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
FDA clears new dual-target cancer drug for ovarian, endometrial trial - Stock Titan
FMR LLC (AVBP) discloses 3.02M shares, 6.8% stake in Arrivent Biopharma - Stock Titan
ArriVent BioPharma: A First Assessment (NASDAQ:AVBP) - Seeking Alpha
Has Amarin (AMRN) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Vicor, AXT And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
Are Medical Stocks Lagging AstraZeneca (AZN) This Year?
Are Medical Stocks Lagging AstraZeneca (AZN) This Year?
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet - Yahoo Finance
Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest
Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest - Yahoo Finance
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year? - Yahoo Finance
ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib (NASDAQ:AVBP) - Seeking Alpha
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?
Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High? - Yahoo Finance
ArriVent BioPharma GAAP EPS of -$4.32 beats by $0.05
ArriVent BioPharma Reports Full Year 2025 Financial Results
ArriVent BioPharma Reports Full Year 2025 Financial Results
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
ArriVent BioPharma, Inc. Common Stock (AVBP) Stock Price Today: $32.54 - Gotrade
ArriVent BioPharma: Its Leading Asset, Furmonertinib, Supports A Cautious Buy - Seeking Alpha
ArriVent BioPharma: Its Leading Asset Furmonertinib Supports A Cautious Buy
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP) - Seeking Alpha
Here Are Tuesday’s Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
12,735 Shares in ArriVent BioPharma, Inc. $AVBP Acquired by AXQ Capital LP
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of “Moderate Buy” from Analysts
We Think ArriVent BioPharma (NASDAQ:AVBP) Needs To Drive Business Growth Carefully
ArriVent BioPharma Reports Third Quarter 2025 Financial Results
ArriVent Appoints Brent S. Rice as Chief Commercial Officer
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer